The relationship between serum adipocytokines and Graves' ophthalmopathy: A hospital-based study
- PMID: 26842711
- DOI: 10.1507/endocrj.EJ15-0478
The relationship between serum adipocytokines and Graves' ophthalmopathy: A hospital-based study
Abstract
Adipocytokines are thought to be associated with inflammatory disorders and autoimmune diseases. However, limited information is available on the relationship between serum adipocytokine levels, Graves' disease (GD), and Graves' ophthalmopathy (GO). The present study examined the relationship between serum adipocytokine levels and GD and GO. A total of 80 patients with GD participated in this study. The medical records of patients were reviewed retrospectively. GO activity was assessed using the clinical activity score (CAS). GO severity was assessed by the modified NOSPECS classification and included soft tissue involvement, proptosis, and extraocular muscle involvement. Serum adiponectin, leptin, resistin, and retinol-binding protein 4 (RBP-4) levels were measured using commercially available enzyme-linked immunosorbent assays. The prevalence of GO was 36.3%. Serum adiponectin, leptin, and resistin levels were significantly higher in patients with GO than in those without GO. The CAS was positively correlated with serum adiponectin and leptin levels. The total eye score was positively correlated with serum adiponectin, leptin, resistin, and RBP-4 levels. A multivariate analysis revealed that serum leptin and resistin levels were associated with the presence of GO after adjusting for clinical factors. Free thyroxine was negatively correlated with serum leptin level. These results suggest that adipocytokines, such as leptin and resistin, may play a role in inflammatory and autoimmune processes of GD and GO. Future studies with larger numbers of patients are required to establish relationships between serum adipocytokines levels and GO and ascertain the role of adipocytokines in GD and GO.
Similar articles
-
Serum concentrations of adiponectin and resistin in hyperthyroid Graves' disease patients.J Endocrinol Invest. 2008 Sep;31(9):745-9. doi: 10.1007/BF03349251. J Endocrinol Invest. 2008. PMID: 18997483
-
Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.Thyroid. 2017 Sep;27(9):1185-1193. doi: 10.1089/thy.2017.0126. Thyroid. 2017. PMID: 28805160
-
Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.J Endocrinol Invest. 2019 Apr;42(4):471-480. doi: 10.1007/s40618-018-0943-8. Epub 2018 Aug 21. J Endocrinol Invest. 2019. PMID: 30132285
-
Decreased nerve growth factor levels in hyperthyroid Graves' ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases.Cytokine. 2006 Aug;35(3-4):109-14. doi: 10.1016/j.cyto.2006.08.002. Epub 2006 Sep 27. Cytokine. 2006. PMID: 17008110 Review.
-
Quality of life and neuropsychiatric disorders in patients with Graves' Orbitopathy: Current concepts.Autoimmun Rev. 2018 Jul;17(7):639-643. doi: 10.1016/j.autrev.2017.12.012. Epub 2018 May 2. Autoimmun Rev. 2018. PMID: 29729448 Review.
Cited by
-
ADIPONECTIN LEVELS IN GRAVES' DISEASE - SYSTEMATIC REVIEW AND META-ANALYSIS.Acta Endocrinol (Buchar). 2023 Jan-Mar;19(1):87-98. doi: 10.4183/aeb.2023.87. Epub 2023 Aug 14. Acta Endocrinol (Buchar). 2023. PMID: 37601709 Free PMC article. Review.
-
Adipocytokines in Graves' orbitopathy and the effect of high-dose corticosteroids.Adipocyte. 2021 Dec;10(1):456-462. doi: 10.1080/21623945.2021.1980258. Adipocyte. 2021. PMID: 34602013 Free PMC article.
-
Interplay between Fatty Acid Binding Protein 4, Fetuin-A, Retinol Binding Protein 4 and Thyroid Function in Metabolic Dysregulation.Metabolites. 2022 Mar 29;12(4):300. doi: 10.3390/metabo12040300. Metabolites. 2022. PMID: 35448487 Free PMC article. Review.
-
The Role of Adipsin, Complement Factor D, in the Pathogenesis of Graves' Orbitopathy.Invest Ophthalmol Vis Sci. 2023 Aug 1;64(11):13. doi: 10.1167/iovs.64.11.13. Invest Ophthalmol Vis Sci. 2023. PMID: 37555734 Free PMC article.
-
ELF3-induced miR-182 inhibits adipogenic differentiation in Graves' orbitopathy by targeting thyrotropin receptor.Cent Eur J Immunol. 2022;47(4):308-322. doi: 10.5114/ceji.2022.124087. Epub 2023 Jan 31. Cent Eur J Immunol. 2022. PMID: 36817393 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous